MARK CEDRIC GILLIES

OPHTHALMOLOGIST

🕻 : (+61) 412 338 075

🖃 : mark.gillies@sydney.edu.au

**PROFILE**

Professor Mark Gillies is the Director of research, Director, Macula Research Group, Save Sight Institute, University of Sydney and Head, Medical Retina Unit, Sydney Eye Hospital. He specializes in medical retina, emerging treatments for macular degeneration and diabetic eye disease. Prof Gillies was the first Australian ophthalmologist to be awarded a PhD, which he received for his work on diabetic retinopathy at the Walter and Eliza Hall Institute. Having trained at Prince of Wales Hospital he moved to the Save Sight Institute after a period of sabbatical study in Boston and London.

**MAJOR POSTS HELD**

* Chair, working group for the International Consortium for Health Outcomes Measurement (2014-2016)
* Chair Scientific Executive Committee, MacTel Project ([www.mactelresearch.org](http://www.mactelresearch.org)), (2005-2013)
* Associate Professor, Dept. Clinical Ophthalmology, University of Sydney (2004-2008)
* Board Member and Chair of Medical Subcommittee, Fred Hollows Foundation (1994-2004)
* Chief Editor, Clinical and Experimental Ophthalmology (1995-2002)
* Qualification and Education Committee, Royal Australian College of Ophthalmologists (1995-2002)
* Co-Scientific Chair, Australian Visual and Ophthalmic Science Conference (1997-2003)
* Visiting Research Fellow, Prof. Alan Bird. Moorfields Eye Hospital, London (1994)

**MEMBERSHIP**

* Macula Society
* Royal Australian New Zealand College of Ophthalmology
* Australian and New Zealand Retina Society
* Association for Research in Vision and Ophthalmology
* Society for Neuroscience
* International Society for Eye Research

**PROFESSIONAL QUALIFICATIONS**

* MB BS (Melb) 1975-1981
* PhD (Medical Biology) 1985-1987
* FRANZCO 1992

**PRESENT POSITIONS HELD**

* Director of Research, Save Sight Institute
* Sydney Medical School Foundation Fellow
* Professor, Dept. Clinical Ophthalmology, The University of Sydney
* Director, Macula Research Group, Save Sight Institute
* Head, Medical Retina Unit, Sydney Eye Hospital
* Deputy Chair, Ophthalmic Research Institute of Australia
* Director, Eye Associates-Level 4, 187 Macquarie Street, Sydney

**ADVISORY / CONSULTENCY**

Member of National and International Ophthalmic (Retinal) Advisory Boards for:

* Allergan Pharmaceuticals
* Pfizer Pharmaceuticals
* Novartis Pharmaceuticals
* Bayer Pharmaceuticals

**CONTENTS**

Invitations, last 10 years 3 - 6

Media, Awards, Conference organization 7

Clinical trials as Chief/ Principal Investigator or Associate Investigator 8 – 12

Publications 13 – 27

Competitive Grants 28 - 35

Research Staff 36

**INVITATIONS, LAST 10 YEARS**

**2018**

* Presenter/Speaker, Allergan IRAB meeting in Vienna, September 2018
* Presenter/Speaker, EURETINA 2018 Congress, Vienna, September 2018
* Speaker, RIVAL Scientific Exchange, Vienna, September 2018
* Panelist/Faculty Speaker, Roudtable discussion “*New Perspective for Your nAMD Patients”*, Vienna, September 2018
* Poster/Attendee, International Forum on Quality and Safety in Healthcare, Melbourne, September 2018
* Speaker, Novartis FDO Symposium, Melbourne, August 2018
* Speaker, Virtual Meeting in Eye Know Hot Topics – 2018, South Africa, August 2018
* Panelist, SEH Biennial Alumni Meeting, Sydney, July 2018
* Speaker, Allergan Beyond Meeting, Sydney, Australia, July 2018
* Speaker, Bayer Global Retinal Network Program (GRNP), Sydney, Australia, June 2018
* Speaker, Spain Retinnova 5.0, Madrid, Spain, May 2018
* Poster/Attendee, Association for Research in Vision and Ophthalmology, Honolulu, Hawaii, May 2018
* Speaker, 43º Congress of the Brazilian Retina and Vitreous Society, Brazil, April 2018
* Speaker, “Anti - VEGF therapy in wAMD  in term of RIVAL interpretation” at Retina Summit, Seoul, March 2018
* Speaker, “Anti - VEGF therapy in wAMD  in term of RIVAL interpretation” at Retina Summit, Vietnam, March 2018
* Speaker, International Retina Auckland, February 2018
* Speaker, Macula Society Meeting Beverly Hills, February 2018
* Speaker, Diabetic Eye Complication Committee, Chinese Research Hospital Association, Beijing, February 2018

**2017**

* Speaker for ‘RETINA LIVE’ event, Kuala Lumpur, December 2017
* Speaker, American Academy of Ophthalmologists (AAO), New Orleans, USA, November 2017
* Speaker, RANZCO Annual Scientific Conference, Perth, November 2017
* Speaker for ‘RETINA LIVE’ event, Singapore and Beijing, October 2017
* Speaker at Future Directions Ophthalmology, Brisbane, September 2017
* Speaker at European Society of Retina Specialists Congress (EURETINA), Barcelona, Sept 2017
* Medical Instructor at Pacific Eye Institute, Fiji, August 2017
* Speaker at Queensland branch RANZCO, August 2017
* Invited Speaker, MaculArt Meeting, Paris, France, July 2017
* Speaker, The 40th Annual Macula Society Meeting, Singapore, June 2017
* Invited Speaker, Macula Symposium
* Speaker, Association for Research in Vision and Ophthalmology, Baltimore, USA, May 2017
* Speaker, ASIA ARVO Conference, Brisbane, QLD, Feb 2017
* Chair, Translational Research Summit, Brisbane, QLD, Feb 2017
* Invited Speaker, ‘Save Sight Institute Lecture’, Save Sight Institute & Sydney Eye Hospital Registrars’ Conference and Teaching Course, Sydney NSW, Jan 2017

**2016**

* Speaker, American Academy of Ophthalmologists (AAO), Chicago, USA, Oct 2016
* Speaker, Oceania Retinal Association Meeting (ORA), Berkeley River, WA, Aug 2016
* ICHOM Scientific Meeting, London, UK, May 2016
* Poster/Attendee, Association for Research in Vision and Ophthalmology, Seattle, USA, May 2016
* Medical Instructor at Pacific Eye Institute, Fiji, APR 2016
* Keynote Speaker, Malaysian Ophthalmological Society, Malaysia, March 2016
* Invited Speaker, East Coast Retina Society, New York, USA, JAN 2016
* Keynote Speaker, Paris Macula Meeting, Paris, France, JAN 2016

**2015**

* Speaker, American Academy of Ophthalmologists (AAO) Retina Day, Plenary Presentation, Las Vegas, USA, Nov 2015
* Speaker, RANZCO Annual Scientific Conference, Wellington NZ, November 2015
* Keynote Speaker, Singapore National Eye Institute Medical Retina Preceptorship program, Singapore, Oct 2015
* Speaker, Oceania Retinal Association Meeting (ORA), Uluru, NT, Aug 2015
* Speaker, Maculart Meeting, Paris, France, Jun 2015
* Speaker, Lebanese Ophthalmological Society, Beirut, Lebanon, Jun 2015
* Speaker, Association for Research in Vision and Ophthalmology, Denver, USA, May 2015
* Speaker, Brisbane Alzheimers and Parkinson’s disease symposium, Queensland Brain Institute, Brisbane QLD, APR 2015
* Speaker, Asia Pacific Academy of Ophthalmology, Guangzhou, China, Apr 2015
* Macular Society, Arizona, USA, Feb 2015

**2014**

* Speaker, RANZCO Annual Scientific Conference ,Brisbane, November 2014
* Speaker, American Academy of Ophthalmologists (AAO), Chicago, USA, Oct 2014
* Speaker, European Society of Retina Specialists Congress (EURETINA), London, UK, Sept 2014
* Speaker, International Congress of Eye Research (ISER), San Francisco, USA, July 2014
* Keynote Speaker, RANZCO NZ branch meeting, Auckland, New Zealand, May 2014
* Association for Research in Vision and Ophthalmology, Orlando, USA, May 2014
* Speaker, World Ophthalmology Congress, Tokyo, Japan, April 2014
* World Conference of Controversies in Ophthalmology, Lisbon, Portugal, March 2014

-Symposium sponsored by Bayer

**2013**

* Invited Speaker, 10th Asia Pacific Vitreo Retinal Society, Nagoya Japan, December 2013
* Speaker, RANZCO Annual Scientific Conference ,Hobart, November 2013
* Speaker, European Congress of Ophthalmology, Copenhagen, Denmark, June 2013
* Speaker, ANZ Retina Society, Sydney, June 2013
* Speaker, Association for Research in Vision and Ophthalmology, Seattle, USA, May 2013

- “Prospective audit of outcomes of treatment of exudative age related macular degeneration: The Fight Retinal Blindness! Project”

* Speaker, The 36th Annual Macular Society Meeting, Dana Point, USA, March 2013
* Invited Speaker and Member of Program Committee for Medical Retina, Asia Pacific Academy of Ophthalmology, Hyderabad, India, January 2013

**2012**

* Invited and Keynote Speaker, RANZCO Annual Scientific Conference: Council Lecture, Melbourne, November 2012
* Invited Speaker, Beijing Tongren Eye Centre 10th Anniversary Symposium, China, September 2012
* Speaker, The 35th Annual Macular Society Meeting, Israel, June, 2012
* Invited Speaker, Association for Research in Vision and Ophthalmology, Florida USA, May 2012

-mini symposium on Translational Medicine

* Invited Speaker, World Ophthalmology Conference, Abu Dhabi, February 2012

-Symposium on anti-vascular endothelial growth factor therapy

**2011**

* Visiting Professor, Centre for Eye Research Australia, Melbourne, September 2011
* Organising Committee and plenary speaker, Pfizer Ophthalmology Forum, Melbourne, July 2011
* Moderator, Poster Session, Macular Disease II, ARVO Fort Lauderdale, May 2011

**2010**

* Invited Speaker, International Society for Ocular Pharmacology and Therapeutics, December 2010, Macau (4 oral presentations)
* Keynote Speaker, Evidence-based Ophthalmology meeting, Flinders University, Adelaide, August 2010
* Invited Speaker, Australian School of Advanced Medicine (ASAM), Macquarie University, Sydney, July 2010
* Invited speaker, World Congress of Ophthalmology, Berlin, June 2010
* Asia Pacific Academy of Ophthalmology, Beijing August 2010
  + Chair and Pacific rim coordinator, Laboratory Science program
* Organising Committee and plenary speaker, Pfizer Ophthalmology Forum, Sydney, June 2010
* Moderator, Paper Session, Diabetic Retinopathy IV: ARVO Fort Lauderdale, May 2010
* Organiser, SIG Idiopathic Macular Telengiectasia Type 2, ARVO Fort Lauderdale, May 2010

**2009**

* Invited speaker, Atlantic Coast Retina Society, New York, January 2009
* Invited speaker, Macula ’09, New York, September 2009
* "Neil Della Lecture" Brisbane 2009
* Invited speaker, XIV Congress of Chinese Ophthalmological Society, Chongqing, September 2009
* Asia Pacific Congress of Ophthalmology, Bali August 2009
  + Chair and Pacific rim coordinator, Laboratory Science program
  + Invited speaker

**MEDIA, AWARDS & CONFERENCE ORGANIZATION**

# Professor Mark Gillies has appeared on numerous occasions in national media (Evening News of all major networks, ABC radio as local expert, see also attached copy of article in *The Australian*) to lobby for Government support for Photodynamic Therapy around 2000-1 (granted 2002), public education on diabetic retinopathy and macular degeneration, most recently to announce results of successful clinical trial of IVTA for diabetic retinopathy

**AWARDS**

* Paper reporting the RCT of triamcinolone for macular degeneration nominated one of the three most significant articles published by *Archives of Ophthalmology* in 2003.
* Presentations of the results of RCTs of IVTA were nominated in 2002, 2003 and 2015 by Association for Research in Vision and Ophthalmology Program Committee (the major meeting in the field) among the top 50 abstracts reporting the newest and most innovative research (of around 6,500) (i.e. top 1% internationally since ARVO is the leading meeting in the field).
* Inducted to the Macular Society 2007, an exclusive international society of around 300 members, mostly academics, that inducts 10 new fellows from around the world per year. There are only 3 Australian members
* Report for TDMO “Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial” was listed among the ten most cited articles in *Ophthalmology*, the leading clinical journal in the field, in the last 5 years in 2011.
* Secretariat Award: Recognised for distinct contributions to the American Academy of Ophthalmology and to the profession of Ophthalmology, 2011.
* Gerard Crock trophy – best paper at the RANZCO Annual Scientific Meeting 2013
* Asia Pacific Academy of Ophthalmology, Achievement Award 2014
* American Academy of Ophthalmology, Achievement Award 2015
* Gerard Crock trophy – best paper at the RANZCO Annual Scientific Meeting 2015
* Invited Faculty member at Association for Research in Vision and Ophthalmology Grant Writing Educational Symposium

**CONFERENCE ORGANIZATIONS**

* *Australian Visual and Ophthalmic Science Conference*: Co-Scientific Chair (1997-2003): meeting grew to 170 delegates, published conference papers in *Clin Exp Ophthalmol*, attendance subsequently slumped
* Member, Local Organizing Committee, International Society for Eye Research, Sydney 2004
* Managed the organization of the *MacTel Project* annual meetings in Los Angeles 2006-2011 (approx. 100 attendees), and MacTel Project mid-term meetings: London 2007-2008, Sydney 2009, London 2010-2011, Sydney 2012 (approx. 50)

**PEER REVIEW**

* NHMRC Panels 2006, 2007, 2010, 2013
* NHMRC Development Grant Panel 2016

**CLINICAL TRIALS**

**AS CHIEF INVESTIGATOR / PRINCIPLE INVESTIGATOR**

***NHMRC FUNDED***

1. Intravitreal triamcinolone for exudative age-related macular degeneration 1997-9 (IVTAS, NHMRC-funded)
2. Chorioretinal venous anastomsis for non-ischaemic central retinal vein thrombosis (CVBS) A 18 month, prospective, multicenter, randomized clinical trial, NHMRC-funded.2004-2005
3. A randomised clinical trial of intravitreal triamcinolone for refractory diabetic macular oedema (TDMO study). 2002-2005
4. TDMX study NHMRC project grant # 402573: An open label extension of a the TDMO study 2006-2008
5. Thunderbird study-NHMRC project grant # 352312: A multicentre randomised clinical trial of laser treatment plus intravitreal triamcinolone for diabetic macular oedema: 2005-2008
6. Genetic risk factors in Diabetic Retinopathy Study, NHMRC project grant #.595918, 2010-2016
7. BEVORDEX Study NHMRC Project grant # 632667**:** A multicentre randomised clinical trial of intravitreal bevacizumab (Avastin®) versus intravitreal dexamethasone (Ozurdex™) for persistent diabetic macular oedema. Phase 2. 2010-2014

***OTHER***

1. Intravitreal Triamcinolone versus laser for macular oedema secondary to Retinal Vein occlusion (ITARVO). A 1- year, prospective, multi-centre, randomised, placebo-controlled trial in patients with branch retinal vein occlusion to assess whether intravitreal triamcinolone was superior to laser treatment.
2. The efficacy and safety of treatment with intravitreal ranibizumab in patients with branch retinal vein occlusion). Multi-centre, randomised, masked, sham-controlled clinical trial. Ongoing
3. Lucentis BRVO: The Efficacy and Safety of Treatment with Intravitreal Ranibizumab in Patients with Branch Retinal Vein Occlusion. Phase 4. 2008-2012
4. TAREDS: Clinical trial of Ranibizumab for Diabetic Macular Oedema resistant to Intravitreal Triamcinolone - IVTA resistant DMO STUDY. Phase 4. 2009-2011
5. SAMTel Study: Sub-study of Mactel Typw 2: Sleep Apnoea and Macular Telangiectasia (SAMTel) pilot Study, 2012-2013
6. PERT Study: Patient Experience in Retinal Trials (PERT) study. 2012-2013
7. Reasons for consequences of long –term discontinuation of ranibizumab treatment for wet age-related macular degeneration. 2012-2013
8. NIRD Trial: Near infrared light photobiomodulation treatment for diabetic macular oedema, 2014-2018

***INDUSTRY SPONSORED***

1. EOP1003: A Phase II/III, randomized, double-masked, controlled, dose ranging, multi-center comparative trial, in parallel groups, to establish the safety and efficacy of Intravitreal injections of EOP001 given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD). 2002-2005
2. EOP1005: A phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula. 2002-2005
3. EOP1011: A phase II randomized, dose ranging, double masked, multi-centre trial, in parrallel groups, to determine the safety and efficacy of intravitreous injections of pegaptanib sodium compared to sham injections for 30 weeks in patients with recent vision loss due to macular oedema secondary to CRVO. 2005-2006
4. Phase 3 study involving oral Ruboxistaurin inReduction in Occurrence of Centre-Threatening Diabetic Macular Edema. (Protocol B7A–MC-MBDL-sponsored by Lilly) 2004-2009
5. EOP1010: An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration (AMD). 2005-2008
6. ANCHOR: A Phase III, multicentre, randomized, double-masked, active treatment-controlled study of the efficacy and safety of RhuFab V2 (Ranibizumab) compared with Verteporfin Photodynamic Therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration. 2004-2006
7. POSURDEX RVO; A six-month phase 3, multicentre, masked, randomised, sham-controlled trial (with six-month open-label extension) to assess the safety and efficacy of 700μg and 350μg dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the treatment of macular swelling at the back of the eye following retinal vein occlusion 2004-2008
8. A Phase II, Randomised, Masked, Single and Multiple- Dose, Sequential Dose Escalation Study of AG-013958 Compound to determine the efficiency and ocular and systemic safety of AG-013958 for 13 weeks following a single administration of ST injection and for 104 weeks following multiple ST injections in subjects with age related macular degeneration. 2006
9. A randomised, double-masked, multi-centred, phase I/II study of the safety of PTK787 administered in conjunction with photodynamic therapy with Visudyne to patients with predominantly classic, minimally classic or occult with no classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. 2006-2008
10. A Natural History of Macular Telangiectasia The Mactel Study: This natural history study, sponsored by the MacTel Foundation, will characterise the clinical features of type IIa idiopathic juxtafoveal telangiectasia (MacTel) and follow how they change over time. 2006-
11. SUSTAIN: A Phase III, Open Label, Multi-centre 12 month study to evaluate the safety, tolerability and efficacy of Ranibizumab (0.3mg) in patients with subfoveal choroidal neovascularisation secondary to age related macular degeneration. 2006-2008
12. SIRIUS Study: A 2-year, Multicenter, Randomized, Controlled, Masked, Dose-Finding Trial to Assess the Safety and Efficacy of Multiple Intravitreal Injections of AGN 211745 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration 2007-2010
13. Posurdex AMD (019): A 26-Week, Open-Label Study to Assess the Safety and Efficacy of 700μg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® in the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular. Phase 2. 2009-2010
14. Posurdex DME VE (018): A 26-Week, Open-Label Study to Assess the Safety and Efficacy of 700μg Dexamethasone Posterior Segment Drug Delivery System Applicator System in the Treatment of Vitrectomized Subjects with Diabetic Macular Edema. Phase 2. 2009-2010
15. Brimo DDS A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Geographic Atrophy from Age-related Macular Degeneration. 2008-2011
16. Posurdex DME (010**):** A Three-Year Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema Protocol Number 206207-010. 2008-2012
17. Restore Study: A Randomized, Double-Masked, Multicenter, Laser Controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-Therapy in Patients with Visual Impairment due to Diabetic Macular Edema. 2008-2010
18. Restore Extension study: A open-label, multicenter, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment visual impairment due to diabetic macular edema in patients who have completed the RESTORE trial. 2010-2012
19. GATE Study: The Safety and Efficacy of AL-8309B Ophthalmic Solution for the treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). 2009-2011
20. View 2 study, VEGF Trap-Eye: A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular degeneration (AMD). 2009-2011.
21. GALILEO VEGF Trap-Eye: A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intavitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO). 2009-2012
22. WALTZ study: RTKi on Wet AMD: A Dose-Escalation Study of AL-39324 Intravitreal Suspension versus Lucentis™ for the Treatment of Exudative Age-Related Macular Degeneration. 2010-2011
23. Study 852:, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration. 2010-2012
24. RVO BDP Study: A 12-Month, Multicenter, 2-stage (Open Label, Dose-Escalation, Followed by Masked, Randomized), Single Dose Study of the Safety and Efficacy of AGN-208397, in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO). 2011-2013
25. VIVID Study: A Randomized, Double-Masked, Active Controlled, phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects with Diabetic Macular Edema**.** 2011-2016
26. Brimo 33D study: A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System. 2012-2013
27. FOVEA Study: A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo‑controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice Daily for the Treatment of Center-involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy. 2012-2013.
28. Luminous Study: Study to observe the effectiveness and safety of LUCENTIS through individualized patient treatment and associated outcomes. 2012-2018
29. MacTel CNTF Study: A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (Protocol NTMT02), 2013-2016
30. MacTel Study: A natural study of macular telangiectasia – The MacTel study. 2005-2015
31. RIVAL Study: Development of new geographic atrophy in patients with neovascular (wet) age-related macular degeneration: a comparison of ranibizumab and aflibercept. 2014-2017
32. CHROMA GX29176 Study**:** A Phase III, Multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered Intrtacitreally to patients with Geographic Atrophy secondary to Age-Related Macular Degeneration. 2014-2016
33. ARIES BAY86-5321/17508 Study: Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept – a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study (ARIES). 2016-
34. OMPASPECT: A Phase IIIb, Multicenter, open-label extension study to evaluate the long term safety and tolerability of Lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a Roche-sponsored study. 2016-2018
35. CNTF Extension: Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) ongoing
36. RENEXUS PhIII: A Phase III Multicenter, Randomized, Sham-Controlled Study to determine the safety and efficacy of Renexus in Macular Telangiectasia Type 2 2017-current
37. KESTREL: Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema 2018-current

**AS ASSOCIATE INVESTIGATOR**

***INDUSTRY SPONSORED***

1. 190342-031D: A multi-center, masked, randomized, sham-controlled, parallel-group, 3 month study with a 9-month safety extension to evaluate the safety and efficacy of brimonidine tartrate posterior segment drug delivery system (Brimonidine Tartrate PS DDS®) applicator system in improving visual function in patients with a previous rhegmatogenous macula-off retinal, 2010-2011
2. ProMEtheus Study: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV), 2013-2015
3. Minerva Study: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) 2013-2015
4. REACH Study:Single Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration. 2012-2013
5. BRIGHTER Study: A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). 2012-2015
6. CRYSTAL Study: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). 2012-2015
7. DARAPLADIB Study: A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of darapladib administered for 3 months to adult subjects with diabetic macular edema with centre involvement. 2012-2013
8. ESBA OWL Microvolume Study: A Prospective, Two Cohort, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration. 2013-2015
9. HAWK Study: A Two-year, Randomized, Double-Masked Multicenter, Three-Arm Study Comparing the Efficacy and safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration. 2015-2016
10. Filly (Apellis) Study:A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA) – FILLY. 2016-
11. SEQUOIA Study: 150998-006: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovacular Age-related Macular Degeneration. 2016-
12. QUARK NAION: QRK-207 : A Phase 2/3, Randomized, Double-Masked,Sham-Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal lnjection(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). 2017-2019.
13. SAPPHIRE: Randomized, masked controlled trial to study the safety and efficacy of suprachoroidal injection in conjunction with intravitreal aflibercept (Eylea®) in subjects with retinal vein occlusion
14. IONIS: Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of ISIS 696844, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
15. TOPAZ: Randomized, masked controlled trial to study the safety and efficacy of suprachoroidal injection in conjunction with anti-VEGF agent in subjects with retinal vein occlusion
16. OAKS: A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
17. RHINE: Phase III, multicenter, randomized, double-masked, active comparator – controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular oedema
18. Conbercept Chengdu: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration

***INVESTIGATOR INITIATED***

1. Switch DMO study:A multicentre clinical trial of switching between intravitreal bevacizumab (Avastin®) and intravitreal dexamethasone (Ozurdex™) for persistent diabetic macular oedema. 2013-2015
2. Speed IOP Study: A randomised clinical trial of slow versus fast intravitreal injection of ranibizumab (lucentis®) and its impact on intraocular pressure. 2012-2013
3. LADAMO: A Phase IV randomised clinical trial of laser therapy for peripheral retinal ischaemia combined with intravitreal aflibercept (Eylea®) versus intravitreal aflibercept monotherapy for diabetic macular oedema. 2015-2018.
4. RADAR: Registry of Advanced DiAbetic Retinopathy. 2016 –

***GOOD CLINICAL PRACTICE (GCP) TRAINING***

31 May 2016 through SEQUOIA clinical trial

**PUBLICATIONS**

***JOURNAL ARTICLES***

1. Chew E, Clemons T, Jaffe G, Johnson C, Farsiu S, Lad E, Guymer R, Rosenfield P, Hubschman JP, Constable I, Wiley H, Singerman L, **Gillies MC**, Comer G, Blodi B, Eliott D, Yan J, Bird A, Friedlander M; Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. Elvieser 2018
2. Midena E, **Gillies M**, Katz TA, Metzig C, Lu C, Ogura Y; Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies. J Ophthalmol 2018; 2018:3640135
3. Lee MG, Marshall NS, Clemons TE, Hunter ML, James AL, Grunstein RR, Nguyen V, Campain A, **Gillies MC**; No association between sleep apnoea and macular telangiectasia type 2 and its markers of severity and progression: a case-controlled study and retrospective cohort study. Clin Exp Ophthalmol 2018; [Epub ahead of print]
4. Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, Morlet N, Hunyor AP, Essex RW, Arnold JJ, **Gillies MC**; Two year outcome of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina 2018; 38:20-28
5. Powner MB, Woods SM, Zhu M, **Gillies MC**, Bernstein PS, Hageman GS, Comer GM, Egan C, Fruttiger M; Fundus-wide subretinal and pigment epithelial abnormalities in macular telangiectasia type 2. Retina 2018; Suppl1:S105-S113
6. Joe AW, Wickremasinghe SS, **Gillies MC**, Nguyen V, Lim LL, Mehta H, Fraser-Bell S; Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab. Clin Exp Ophthalmol. 2018; [Epub ahead of print] PMID: 30084193
7. Mantel I, **Gillies MC**, Souied EH; Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Surv Ophthalmol. 2018; 63(5):638-645 PMID 29476754
8. Invernizzi A, Nguyen V, Arnold J, Young S, Barthelmes D, **Gillies MC**; Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018 125(2):237-244 PMID 28993010
9. Mehta H, Fraser-Bell S, Nguyen V, Lim LL, **Gillies MC;** Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema. Br J Ophthalmol. 2018 102(4):479-482 PMID: 28779007
10. Shen W, Lee SR, Yam M, Zhu L, Zhang T, Pye V, Mathai AE, Shibagaki K, Zhang JZ, Matsugi T and Gillies MC. A combination therapy targeting endoglin and VEGF-A prevents subretinal fibro-neovascularization caused by induced Müller cell disruption. Invest Ophthalmol Vis Sci *(accepted 04/11/2018).*
11. Ting KK, Zhao Y, Shen W, Coleman P, Li J, Moller T, Gillies MC, Vadas MA and Gamble JR. Therapeutic regulation of VE-Cadherin with a novel oligonucleotide drug for diabetic eye complications. *Diabetologia (accepted 03/10/2018*).
12. Simunovic MP, Shen W, Lin JY, Protti DA, Likowski L and Gillies MC. Optogenetic approaches to vision restoration. Exp Eye Res 2019;178:15-26.
13. Irhimeh MR, Hamed M, Barthelmes D, Gladbach Y, Helms V, Shen W and Gillies MC. Identification of novel diabetes impaired miRNA-transcription factor co-regulatory networks in bone marrow-derived endothelial progenitor cells. *PLOS One* 2018; 13 (7), e0200194.
14. Zhu L, Shen W, Wang Y, Zhang T, Bahrami B, Zhou F, Gillies MC. Characterization of canonical Wnt signalling changes after induced Müller cell disruption in murine retina. *Exp Eye Res* 2018;175:173-180
15. Zhang T, Mark MC, Madigan MC, Shen W, Du J, Grunert U, Zhou F, Yam M and Zhu L. Disruption of de novo serine synthesis in Müller glia cells induced mitochondrial dysfunction and aggravated oxidative damage. *Mol Neurobiol* 2018;55:7025-7037*.*
16. Nguyen V, Daien V, Guymer R, Young S, Hunyor A, Fraser-Bell S, Hunt A, **Gillies MC**, Barthelmes D, Fight Retinal Blindness! Study Group; Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology 2018; [Epub ahead of print]
17. Nguyen V, Daien V, Guymer RH, McAllister IL, Morlet N, Barthelmes D, **Gillies MC**; Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project. Clin Exp Ophthalmol. 2018 46(3):266-274. PMID 28842956
18. Barthelmes D, Nguyen V, Walton R, **Gillies MC**, Daien V; Fight Retinal Blindness Study Group; A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project. Graefes Arch Clin Exp Ophthalmol 2018; [Epub ahead of print]
19. Mehta H, Hennings C, **Gillies MC**, Nguyen V, Campain A, Fraser-Bell S; Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 2018 4:CD011599
20. Daien V, Nguyen V, Morlet N, Arnold JJ, Essex RW, Young S, Hunyor A, **Gillies MC**, Barthelmes D; Fight Retinal Blindness! Study Group; Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project. Am J Ophthalmol 2018;190:50-57
21. Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, **Gillies MC**; Fight Retinal Blindness! Study Group.

Incidence and Outcomes of Infectious and Non-infectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. Ophthalmology 2018; [Epub ahead of print] PMID: 28801117

1. Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, Barthelmes D, **Gillies MC**; Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res 2018; [Epub ahead of print] PMID: 29305324
2. Essex RW, Nguyen V, Daien V, Steinmann S, Walton R, **Gillies MC**, Barthelmes D; Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study. Br J Ophthalmol. 2018;  [Epub ahead of print] PMID:30385435
3. Simunovic MP, Shen W, Lin JY, Protti DA, Lisowski L, **Gillies MC**; Optogenetic approaches to vision restoration. Exp Eye Res. 2018; [Epub ahead of print] PMID:30218651
4. Graham PS, Kaidonis G, Abhary S, **Gillies MC**, Daniell M, Essex RW, Chang JH, Lake SR, Pal B, Jenkins AJ, Hewitt AW, Lamoureux EL, Hykin PG, Petrovsky N, Brown MA, Craig JE, Burdon KP; Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. BMC Med Genet. 2018 [Epub ahead of print] PMID:29739359
5. Vaze A, Nguyen V, Daien V, Arnold JJ, Young SH, Cheung CM, Lamoureux E, Bhargava M, Barthelmes D, **Gillies MC**; Fight Retinal Blindness Study Group; Ranibizumab and aflibercept for the treatment of pigment epithelial detachment in neovascular age-related macular degeneration: data from an observational study. Retina. 2018 38(10):1954-1961 PMID 28820848
6. Ao J, Wood JP, Chidlow G, **Gillies MC**, Casson RJ; Retinal pigment epithelium in the pathogenesis of age-related macular degeneration and photobiomodulation as a potential therapy? Clin Exp Ophthalmol 2017; 46:670-686
7. Powner MB, Woods SM, Zhu M, **Gillies MC**, Bernstein PS, Hageman GS, Comer GM, Egan C, Fruttiger M; Fundus-wide subretinal and pigment epithelial abnormalities in mactel telangiectasia type 2. Retina 2017; [Epub ahead of print] PMID: 29045321
8. Ozturk M, Harris ML, Nguyen V, Barthelmes D, **Gillies MC,** Mehta H; Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence. Clin Exp Ophthalmol 2017; [Epub ahead of print] PMID: 29044979
9. Invernizzi A, Nguyen V, Arnold J, Young S, Barthelmes D, **Gillies MC**; Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology 2017; [Epub ahead of print] PMID: 28993010
10. Nguyen V, Daien V, Guymer RH, McAllister IL, Morlet N, Barthelmes D, **Gillies MC**; Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project. Clin Exp Ophthalmol 2017; [Epub ahead of print] PMID: 28842956
11. Mehta H, Fraser-Bell S, Nguyen V, Lyndell LL, **Gillies MC;** The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial. Opthal Retina 2017; ISSN 2468-6530
12. Baumann B, Sterling J, Song Y, Song D, Fruttiger M, **Gillies M**, Weiyong S, Dunaief JL; Conditional Muller Cell Ablation leads to Retinal Iron Accumulation. Invest Opthalmol Vis Sci 2017; 15:4223-4234
13. Vaze A, Nguyen V, Daien V, Arnold JJ, Young SH, Cheung CM, Lamoureux E, Bhargava M, Barthelmes D, **Gillies MC;** Fight Retinal Blindness Study Group. Ranibizumab and aflibercept for the treatment of pigment epithelial detachment in neovascular age-related macular degeneration: Data from an observational study. Retina 2017; [Epub ahead of print] PMID: 28820848
14. Mehta H, Fraser-Bell S, Nguyen V, Lim LL, **Gillies MC**. Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema. Br J Ophthalmol 2017; [Epub ahead of print] PMID: 28779007
15. Shen W, Yau B, Lee SR, Zhu L, Yam M, **Gillies MC**. Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions. Int J Mol Sci 2017; 18. PMID: 28257068
16. Wickremasinghe SS, Fraser-Bell S, Alessandrello E, Mehta H, **Gillies MC**, Lim LL. Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema. Br J Ophthalmol 2017; [Epub ahead of print] PMID: 28228411
17. **Gillies MC**, Daien V, Nguyen V, Barthelmes D. Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761). Ophthalmology 2017;124:e31-32. PMID: 28219517
18. Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, Morlet N, Hunyor AP, Essex RW, Arnold JJ, **Gillies MC**; Fight Retinal Blindness Study Group. Two Year Outcomes of ‘Treat and Extend’ Intravitreal therapy using Aflibercept preferentially for neovascular age-related macular degeneration. Retina 2017; [Epub ahead of print] PMID: 28145976
19. Tao Z, Zhao C, Jian Q, **Gillies M,** Xu H, Yin ZQ. Lin. 28B promotes Müller glial cell de-differentiation and proliferation in the regenerative rat retinas. Oncotarget 2016;7:49368-49383
20. Kim LN, Mehta H, Barthelmes D, Nguyen V, **Gillies MC**. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2016; 36:1418-31. PMID:
21. Mehta H, Müller S, Egan CA, Degli Esposti S, Tufail A, Sim DA, Holz FG, Browning AC, Amoaku WM, Charbel Issa P, **Gillies MC**. Natural history and effect of therapeutic interventions on subretinal fluid causing foveal detachment in macular telangiectasia type 2. Br J Ophthalmol 2016; 101:955-959. PubMed PMID: 27793821.
22. Razavi H, Walton R, **Gillies M**, Guymer R; Fight Retinal Blindness! Project Investigators. Seven-year Trends in Visual Acuity at First Presentation in Patients with Neovascular AMD. Ophthalmology. 2016 Sep 2. [Epub ahead of print] PubMed PMID: 27596290.
23. Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, Morlet N, Young S, Barthelmes D, **Gillies MC**; Fight Retinal Blindness Study Group. Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration. Ophthalmology 2016; 123:2393-2400. PMID: 27554034
24. **Gillies MC**, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology. 2016;123:2545-2553.
25. Aroney C, Fraser-Bell S, Lamoureux EL, **Gillies MC**, Lim LL, Fenwick EK. Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A Clinical Trial Comparing Ozurdex Sustained Release Dexamethasone Intravitreal Implant and Bevacizumab Treatment for Diabetic Macular Edema. Invest Ophthalmol Vis Sci 2016; 57:5541-5546. PMID: 27768792
26. Chung SH, **Gillies M**, Yam M, Wang Y, Shen W. Differential expression of microRNAs in retinal vasculopathy caused by selective Müller cell disruption. Sci Rep. 2016;6:28993.
27. Daien V, Papinaud L, **Gillies MC,** Domerg C, Nagot N, Lacombe S, Daures JP, Carriere I, Villain M. Effectiveness and Safety of an Intracameral Injection of Cefuroxime for the Prevention of Endophthalmitis After Cataract Surgery With or Without Perioperative Capsular Rupture. JAMA Ophthalmol 2016; 134:810-816. PMID: 27388744
28. Kaidonis G, Craig JE, **Gillies MC**, Abhary S, Essex RW, Chang JH, Pal B, Pefkianaki M, Daniell M, Lake S, Petrovsky N, Burdon KP. Promoter polymorphism at the tumour necrosis factor/lymphotoxin-alpha locus is associated with type of diabetes but not with susceptibility to sight-threatening diabetic retinopathy. Diab Vasc Dis Res 2016; 13:164-7. PMID: 26821796
29. Kaidonis G, **Gillies MC,** Abhary S, Liu E, Essex RW, Chang JH, Pal B, Sivaprasad S, Pefkianaki M, Daniell M, Lake S, Petrovsky N, Hewitt AW, Jenkins A, Lamoureux EL, Gleadle JM, Craig JE, Burdon KP. A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. Acta Diabetol 2016; 53:643-650. PMID: 26997512
30. Barthelmes D, Campain A, Nguyen P, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, Guymer R, Essex RW, Morlet N, **Gillies MC**; Fight Retinal Blindness! Project Investigators. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol 2016; 100:1640-1645. PMID: 26994110
31. Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, Li J, Quin GJ, McAllister IL, **Gillies MC**. Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). Ophthalmology 2016; 123:1399-401. PMID: 26783096
32. Mehta H, **Gillies MC,** Fraser-Bell S. Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review. Clin Experiment Ophthalmol 2016; 44:335-9. PMID: 27061760
33. Rodrigues IA, Sprinkhuizen SM, Barthelmes D, Blumenkranz M, Cheung G, Haller J, Johnston R, Kim R, Klaver C, McKibbin M, Ngah NF, Pershing S, Shankar D, Tamura H, Tufail A, Weng CY, Westborg I, Yelf C, Yoshimura N, **Gillies MC**. Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. Am J Ophthalmol 2016; 168:1-12. PMID: 27136069
34. Xu C, Zhu L, Chan T, Lu X, Shen W, Madigan MC**, Gillies MC**, Zhou F. Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2. J Pharm Sci. 2016;105:884-90.
35. Mehta H, **Gillies M**, Fraser-Bell S. Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. Ther Adv Chronic Dis. 2015; 6:234-45.
36. Qatarneh, D; Lim, L; Hodgson, L; Mehta, H Fraser-Bell, S; **Gillies, M**. Diabetic Retinopathy Progression in the Bevordex Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Dexamethasone for Diabetic Macular Oedema. 2015. Clin Experiment Ophthalmol. 43:28-28
37. Zheng L, **Gillies M**, Martin FJ. Central retinal vein occlusion in an otherwise healthy child treated successfully with a single injection of bevacizumab. JAAPOS. 2015;19:473-4.
38. Burdon KP, Fogarty RD, Shen W, Abhary S, Kaidonis G, Appukuttan B, Hewitt AW, Sharma S, Daniell M, Essex RW, Chang JH, Klebe S, Lake SR, Pal B, Jenkins A, Govindarjan G, Sundaresan P, Lamoureux EL, Ramasamy K, Pefkianaki M, Hykin PG, Petrovsky N, Brown MA, **Gillies MC**, Craig JE. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia. 2015;58:2288-97.
39. **Gillies MC**, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, Essex RW, Morlet N, Hunyor AP; Fight Retinal Blindness Study Group. Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology. 2015;122:1837-45.
40. Au CP, Fardell N, Williams M, Fraser-Bell S, Campain A, **Gillies M.** Patient experiences in retinal trials: a cross-sectional study. BMC Ophthalmol. 2015;15:80.
41. Mehta H, Fraser-Bell S, Yeung A, Campain A, Lim LL, Quin GJ, McAllister IL, Keane PA, **Gillies MC**. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. Br J Ophthalmol 2016; 100:1000-1014. PMID: 26537156
42. Kaidonis G, Burdon KP, **Gillies MC,** Abhary S, Essex RW, Chang JH, Pal B, Pefkianaki M, Daniell M, Lake S, Petrovsky N, Hewitt AW, Jenkins A, Lamoureux EL, Gleadle JM, Craig JE. Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema. Ophthalmology. 2015;122:1828-36.
43. **Gillies MC**, Mehta H, Bird AC. Macular Telangiectasia Type 2 Without Clinically Detectable Vasculopathy. JAMA Ophthalmol. 2015;133:951-4.
44. Chung SH, Shen W, **Gillies M**. Genomic analysis using Affymetrix standard microarray genechips (169 format) in degenerate murine retina. Methods Mol Biol. 2015;1254:129-40.
45. Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, **Gillies MC;** Fight Retinal Blindness Study Group. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;12:1212-9.
46. Xu C, Zhu L, Chan T, Lu X, Shen W, **Gillies MC**, Zhou F. The altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic mice. PLoS One. 2015;10:e0120760.
47. Chung SH, **Gillies M**, Sugiyama Y, Zhu L, Lee SR, Shen W. Profiling of microRNAs involved in retinal degeneration caused by selective Müller cell ablation. PLoS One. 2015;10:e0118949.
48. Coorey NJ, Shen W, Zhu L, **Gillies MC**. Differential expression of IL-6/gp130 cytokines, JAK-STAT signalling and neuroprotection after Müller cell ablation in a transgenic mouse model. Invest Ophthalmol Vis Sci. 2015;56:2151-61
49. Zhu L, Shen W, Lyons B, Wang Y, Zhou F, **Gillies MC**. Dysregulation of inter-photoreceptor retinoid-binding protein (IRBP) after induced Müller cell disruption. J Neurochem. 2015;133:909-18.
50. Chan T, Zhu L, Madigan MC, Wang K, Shen W, **Gillies MC**, Zhou F. Human organic anion transporting polypeptide 1A2 (OATP1A2) mediates cellular uptake of all-trans-retinol in human retinal pigmented epithelial cells. Br J Pharmacol.2015;172:2343-53.
51. **Gillies MC**, Campain A, Walton R, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, Hunyor AP, Essex RW, Morlet N, Barthelmes D; Fight Retinal Blindness Study Group\*. Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily with Ranibizumab. Ophthalmology. 2015;122:589-594.e1.
52. Quin GJ, Lyons B, Len AC, Madigan MC**, Gillies MC**. Proteome changes induced by laser in diabetic retinopathy. Clin Experiment Ophthalmol. 2015;43:180-7.
53. Barthelmes D, Walton R, Campain AE, Simpson JM, Arnold JJ, McAllister IL, Guymer RH, Hunyor AP, Essex RW, Morlet N, **Gillies MC**; for the Fight Retinal Blindness! Project Investigators. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. Br J Ophthalmol. 2015;99:359-64.
54. Shibeeb O, Vaze A, **Gillies M,** Gray T. Macular oedema in idiopathic macular telangiectasia type 1 responsive to aflibercept but not bevacizumab. Case Rep Ophthalmol Med. 2014;2014:219792
55. Chung, S. H., Shen, W., & **Gillies, M**. Identification of a novel miRNA targeting CD146 for suppression of angiogenesis. Non-coding RNAs in Endocrinology. 2014;1:28-30.
56. O'Day RF, Barthelmes D, Zhu M, Wong TY, McAllister IL, Arnold JJ, **Gillies MC**. Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial. BMC Ophthalmol. 2014;14:123.
57. **Gillies MC**, Lim LL, Campain A, Quin GJ, Salem W, Li J, Goodwin S, Aroney C, McAllister IL, Fraser-Bell S. A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema: The BEVORDEX Study. Ophthalmology. 2014;121:2473-81.
58. Shen W, Chung SH, Irhimeh MR, Li S, Lee SR, **Gillies MC**. Systemic administration of erythropoietin inhibits retinopathy in RCS rats. PLoS One. 2014;9:e104759.
59. Zhang X, Zeng H, Bao S, Wang N, **Gillies MC**. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27.
60. Barthelmes D, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Campain A, Hunyor AP, Guymer R, Essex RW, Morlet N, **Gillies MC**; for the Fight Retinal Blindness! Project Investigators. Intravitreal Therapy in Bilateral Neovascular Age-Related Macular Degeneration. Ophthalmology. 2014;121:2073-4.
61. Vaze A, Fraser-Bell S, **Gillies M**. Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration. Retina. 2014:34:1774-8.
62. Vaze A, Fraser-Bell S, **Gillies M**. Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92:e697-8.
63. Shen W, Lee SR, Araujo J, Chung SH, Zhu L, **Gillies MC**. [Effect of glucocorticoids on neuronal and vascular pathology in a transgenic model of selective Müller cell ablation.](http://www.ncbi.nlm.nih.gov/pubmed/24687761) Glia. 2014; 62:1110-24.
64. Finger RP, Guymer RH, **Gillies MC**, Keeffe JE. The Impact of Anti-Vascular Endothelial Growth Factor Treatment on Quality of Life in Neovascular Age-related Macular Degeneration. Ophthalmology. 2014;121:1246-51.
65. Barthelmes D, Zhu, L, Shen W, **Gillies MC**, Irhimeh MR. Differential gene expression in Lin-/VEGF-R2+ bone marrow-derived endothelial progenitor cells isolated from diabetic mice. Cardiovascular Diabetology. 2014;13:42.
66. Zhang X, Wang N, Schachat AP, Bao S, **Gillies MC**. Glucocorticoids: Structure, Signaling and Molecular Mechanisms in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema. Curr Mol Med. 2014;14:376-84
67. O'Day R, Walton R, Blennerhassett R, **Gillies MC**, Barthelmes D. Reporting of Harms by Randomised Controlled Trials in Ophthalmology. Br J Ophthalmol. 2014;98:1003-8.
68. **Gillies MC**, Walton R, Liong J, Arnold JJ, McAllister I, Morlet N, Hunyor A, Guymer R, Keeffe J, Essex R , Herrera-Bond A, Glastonbury B, Simpson JM, Barthelmes D. Efficient capture of high quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project. Retina. 2014;34:188-95.
69. Tan MH, McAllister IL, **Gillies MC**, Verma N, Banerjee G, Smithies LA, Wong WL, Wong TY. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol. 2014;157:237-247.
70. **Gillies MC**., Walton RJ., Arnold JJ., McAllister IL., Simpson JM., Hunyor AP., Guymer R., Essex RW., Morlet N., Barthelmes D. Comparison of outcomes from a Phase III Study of Age-Related Macular Degeneration with matched observational cohort ophthalmology. Ophthalmology. 2014;121:676-81.
71. Kaidonis G., Abhary S., Daniell M., **Gillies M.,** Fogarty R., Petrovsk N., Jenkins N., Essex R., Chang JH., Pal B, Hewitt AH, Burdon KP, Craig JE, The Genetic Study of Diabetic Retinopathy: Recruitment methodology and analysis of baseline characteristics**.** Clin Experiment Ophthalmol. 2014;42:486-93.
72. Zhu, L., Shen, W., Zhu, M., Coorey, N. J., Nguyen, A. P., Barthelmes, D. and **Gillies MC**. Anti-retinal antibodies in patients with Macular Telangiectasia Type 2. Invest Ophthalmol Vis Sci. 2013;54:5675-83
73. O'Day R, **Gillies MC**, Ahlenstiel G. Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol. 2013;19:8227-8237.
74. Shen W, Zhu L, Lee SR, Chung SH, **Gillies MC**. Involvement of NT3 and P75NTR in photoreceptor degeneration following selective Müller cell ablation. J Neuroinflammation. 2013;10:137.
75. Barthelmes D, Irhimeh MR, **Gillies MC**, Karimipour M, Zhou M, Zhu L, Shen WY, Diabetes impairs mobilization of mouse bone marrow-derived Lin-/VEGF-R2+progenitor cells. Blood Cells Mol Dis. 2013;51:163-73
76. **Gillies MC,** Walton R, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, Hunyor AP, Essex RW, Morlet N, Barthelmes D; Fight Retinal Blindness! Project Investigators. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Invest Ophthalmol Vis Sci. 2013;54:5754-60
77. Holz FG, Bandello F, **Gillies M**, Mitchell P, Osborne A, Sheidow T, Souied E,Figueroa MS; LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013;97:1161-7
78. O'Day R, Barthelmes D, Zhu M, Wong TY, McAllister IL, Arnold JJ, **Gillies MC**. Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema. Clin Ophthalmol. 2013;7:1565-70.
79. Chung SH, Shen W, **Gillies MC**. Laser Capture Microdissection-Directed Profiling of Glycolytic and mTOR Pathways in Areas of Selectively ablated Muller Cells in the Murine Retina. Invest Ophthalmol Vis Sci. 2013; 9;54:6578-85.
80. Barthelmes D, Irhimeh MR, **Gillies MC**, Zhu L, Shen WY. Isolation and characterization of mouse bone marrow-derived Lin-/VEGF-R2+ progenitor cells. Ann Hematol. 2013;92:1461-72.
81. Chung SH, Shen W, Jayawardana K, Wang P, Yang J, Shackel N, **Gillies MC.** Differential Gene Expression Profiling After Conditional Müller Cell Ablation In A Novel Transgenic Model. Invest Ophthalmol Vis Sci. 2013;54:2142-52
82. Zhang X, Wang N, Bao B, **Gillies M**. Diabetic Retinopathy: Neuron Protection as a Therapeutic Target. Int J Biochem Cell Biol. 2013;45:1525-9
83. Zhang X, Lai D, Bao S, Hambly BD, Wang N, **Gillies MC**. Triamcinolone acetonide inhibits p38mapk activation and neuronal apoptosis in early diabetic retinopathy. Curr Mol Med. 2013;13:946-58
84. Clemons TE, **Gillies MC**, Chew EY, Bird AC, Peto T, Wang JJ, Mitchell P, Ramdas WD, Vingerling JR. Medical Characteristics of Patients with Macular Telangiectasia Type 2 (MacTel Type 2). Ophthalmic Epidemiol. 2013;20:109-13
85. Powner MB, **Gillies MC**, Zhu M, Kristis Vevis K, Hunyor, AP, Fruttiger M. Loss of Müller cells and photoreceptors in Macular Telangiectasia Type 2. Ophthalmology. 2013;120:2344-52.
86. Charbel Issa P, **Gillies MC**, Chew EY, Bird AC, Heeren T, Peto T, Holz FG, Scholl HPN. Macular Telangiectasia Type 2. Prog Retin Eye Res. 2013;34:49-77
87. Zhu M, Krillis M, **Gillies MC**. The relationship between inner and outer retinal cavitation and the integrity of the outer limiting membrane in Macular Telangiectasia Type 2. Retina. 2013;33:1547-50.
88. Kemp A, Preen DB, Morlet N, Clark A, McAllister IL, Briffa T, Sanfilippo F, Ng JQ, McKnight C, Reynolds W, **Gillies MC**. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study. Retina. 2013;33:920-7
89. Liew G, Quin G, **Gillies M**, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2013;41:201-14
90. Quin G, Liew G, Ho IV, **Gillies M**, Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Experiment Ophthalmol. 2013;41:187-200
91. Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UE, Clemons TE, **Gillies MC,** Pauleikhoff D, Rubin GS, Chew EY, Bird AC; MacTel Study Group. [The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia.](http://www.ncbi.nlm.nih.gov/pubmed/23092925)Invest Ophthalmol Vis Sci. 2012;53:7889-95
92. McAllister IL, **Gillies MC**, Smithies LA, Rochtchina E, Harper CA, Daniell MD, Constable IJ, Mitchell P. [Factors Promoting Success and Influencing Complications in Laser-Induced Central Vein Bypass.](http://www.ncbi.nlm.nih.gov/pubmed/22959103) Ophthalmology. 2012;119:2579-86
93. Shen W, Fruttiger M, Zhu L, Chung SH, Barnett NL, Kirk JK, Lee S, Coorey NJ, Killingsworth M, Sherman LS, **Gillies MC.** Conditional Muller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model. J Neurosci 2012;32:15715-15727
94. Cherepanoff S, Killingsworth MV, Zhu M, Nolan T, Hunyor AP, Young SH, Hageman GS, **Gillies MC**. Ultrastructural and clinical evidence of subretinal debris accumulation in type 2 macular telangiectasia. Brit J Ophthalmol. 2012;96:1404-9
95. Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UE, Clemons TE, **Gillies MC**, Pauleikhoff D, Rubin GS, Chew EY, Bird AC. 'En face' OCT imaging of the IS/OS junction line in Type 2 Idiopathic Macular Telangiectasia. Invest Ophthalmol Vis Sci. 2012;53:6145-52
96. Salem W, Fraser-Bell S, **Gillies M**. [Clinical development of new treatments for diabetic macular oedema.](http://www.ncbi.nlm.nih.gov/pubmed/22428627) Clin Exp Optom. 2012;95:297-305.
97. Jay NL, **Gillies M**. Proteomic analysis of ophthalmic disease. Clin Experiment Ophthalmol. 2012;40:755-63
98. Coorey NJ, Shen W, Chung SH, Zhu L, **Gillies MC.** The role of glia in retinal vascular disease. Clin Exp Optom. 2012;95:266-81.
99. Zhang X, Chen M, **Gillies MC**. Two Isoforms of Flk-1 Transcripts in Early Diabetic Rat Retinas. Current Eye Research. 2012;37:73-9
100. Len A, Powner M, Zhu L, Hageman G, Song X, Fruttiger M, **Gillies M**. Pilot application of iTRAQ to the retinal disease Macular Telangiectasia. J Proteome Res. 2011;11:537-553
101. **Gillies MC**, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, Wong TY. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology. 2011;118:866-72
102. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, **Gillies M,** Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group. Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion Twelve-Month Study Results. Ophthalmology. 2011;118:2453-2460
103. Powner MB, Scott A, Zhu M, Munro PM, Foss AJ, Hageman GS, **Gillies MC**, Fruttiger M. Basement membrane changes in capillaries of the ageing human retina. Br J Ophthalmol. 2011; 95:1316-1322
104. Shen W, Li S, Chung SH, Zhu L, Stayt J, Su T, Couraud P-O, Romero IA, Weksler B **Gillies MC.** Tyrosine phosphorylation of VE-cadherin and claudin-5 is associated with TGF-β1-induced permeability of centrally-derived vascular endothelium. European J Cell Biol 2011;90:323-32
105. Shen W, Zhang J, Chung SH, Hu Y, Ma Z, **Gillies MC**. Submacular DL-alpha-aminoadipic acid eradicates primate photoreceptors but does not affect luteal pigment or the retinal vasculature. Invest Ophthalmol Vis Sci. 2011; 52:119-27
106. Powner MB, **Gillies MC**, Tretiach M, Scott A, Guymer RH, Hageman GS, Fruttiger M. Perifoveal Müller Cell Depletion in a Case of Macular Telangiectasia Type 2. Ophthalmology. 2010;117:2407-16
107. **Gillies MC**. Bevacizumab in ophthalmology: the controversy moves forward. Clin Experiment Ophthalmol. 2010;3:333-4
108. Szental JA, Baird PN, Richardson AJ, Islam FM, Scholl HP, Charbel Issa P, Holz FG, **Gillies M**, Guymer RH. Analysis of glutathione S-transferase Pi isoform (GSTP1) single-nucleotide polymorphisms and macular telangiectasia type 2. Int Ophthalmol. 2010;30:645-50
109. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, **Gillies M**, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146
110. **Gillies MC**, Islabevom FM, Larsson J, Pasadhika S, Gaston C, Zhu M, Wong TY. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomised clinical trial. Clin Experiment Ophthalmol.2010;38:605-12
111. Parmalee NL, Schubert C, Merriam JE, Allikmets K, Bird AC, **Gillies MC,** Peto T, Figueroa M, Friedlander M, Fruttiger M, Greenwood J, Moss SE, Smith LE, Toomes C, Inglehearn CF, Allikmets R. Analysis of candidate genes for macular telangiectasia type 2. Mol Vis. 2010;16:2718-26
112. Kuo CH, **Gillies MC,** McCluskey P. Intraocular Triamcinolone for Giant Cell Arteritis? Arch Ophthalmol. 2010;128:1633.
113. Kuo CH, McCluskey P, **Gillies M**. Pharmacotherapeutic efficacy of preservative-free intravitreal triamcinolone acetonide. Expert Opin Pharmacother. 2010:155-66
114. Cherepanoff S, McMenamin PG, **Gillies MC**, Kettle E, Sarks SH. Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol. 2010;94:918-25
115. McAllister I, **Gillies M**, Smithies L, Rochtchina E, Harper A, Daniell M, Constable I, Mitchell P: The Central Retinal Vein Bypass Study: A randomised controlled multi-centre trial of laser-induced chorioretinal venous anastomosis for non-ischaemic central retinal vein occlusion. Ophthalmology.2010;117:954-965
116. Shen W, Li S, Chung SH, **Gillies MC**. Retinal Vascular Changes after Glial Disruption in Rats. J Neurosci Res. 2010;15;88:1485-99.
117. Clemons TE, **Gillies MC**, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW and theMacular Telangiectasia Research Group. Baseline Characteristics of Participants in the Natural History Study of Macular Telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiol. 2010;17:66-73
118. **Gillies MC**, McAllisterIL, Zhu M, WongW, LouisD, ArnoldJJ, WongTY. Pre-Treatment with Intravitreal Triamcinolone Prior to Laser for Diabetic Macular Edema: 6-Month Results of a Randomised, Placebo-Controlled Trial. Invest. Ophthalmol. Vis. Sci. 2010;51:2322-2328
119. Zhang X, Bao S, Hambly BD, **Gillies MC**. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem & Cell Biol., 2009;41:2368-2371
120. Kuo CH, **Gillies MC**. Role of steroids in the Treatment of Diabetic Macular Edema. International Ophthalmology Clinics 2009;49:121-134
121. **Gillies MC,** Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, Sutter FKP. 5-year results of a randomized clinical trial with open label extension of intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2009;116:2182-2187.
122. **Gillies MC**, Zhu M, Chew E, Barthelmes D, Hughes E, Ali H, Holz FG, Scholl H, Issa PC. Familial Asymptomatic Macular Telangiectasia Type 2. Ophthalmology. 2009;116:2422-2429
123. **Gillies MC**, Simpson JM, Zhu M. Hunt G, Ali H, Gaston C. Intravitreal Triamcinolone. Ophthalmology. 2009;116:591
124. **Gillies M**. Diabetic macular edema. Ophthalmology. 2009;116:595; Author reply 596-7.
125. Tikellis G, **Gillies M**, Guymer RH, McAllister I, Shaw J, Wong TY. Retinal Vascular Caliber and Macular Telangiectasia Type 2. Ophthalmology. 2009;116:319-23
126. **Gillies M.** Intravitreal triamcinolone for diabetic macular edema. Ophthalmology 2009;116;591.
127. Clemons TE, **Gillies** MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW; Macular Telangiectasia Research Group: The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. Invest Ophthalmol Vis Sci 2008;49:4340-6
128. Wickremasinghe SS, Rogers SL, **Gillies MC**, Zhu M, Wong TY. Retinal Vascular Caliber Changes after Intravitreal Triamcinolone Treatment for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2008;49:4707-11
129. Fischer MD, Fleischhauer JC, **Gillies MC**,Sutter FKP, Helbig H, Barthelmes D**.** A New Method To Monitor Visual Field Defects Caused By Photoreceptor Degeneration Using Quantitative Optical Coherence Tomography. Invest Ophthalmol Vis Sci 2008;49:3617-21
130. Barthelmes D,Sutter FKP, **Gillies MC**, Differential Optical Densities of Intraretinal Spaces. Invest Ophthalmol Vis Sci. 2008;49:3529-34
131. Liew G, **Gillies M**, Wang JJ. Fenofibrate and diabetic retinopathy. Lancet. 2008;371(9614):721
132. Larsson J, Kifley A, Zhu M, Wang JJ, Mitchel P, Sutter FKP, **Gillies MC**. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone – Data from randomized, placebo controlled trial. Acta Opthalmologica 2009; 87:275-80
133. Barthelmes D,**Gillies MC**, Sutter FKP.[Quantitative OCT Analysis of Idiopathic Perifoveal Telangiectasia](javascript:%20void(window.open('main.html?mode=view_for_review&man_hash=e974b98a0c2f1d8e804b190a7ab40b3a&sessionid=c3ce3e6f0343fc3e4a930d59e41d6435','','toolbar=no,scrollbars=yes,resizable=yes,location=no,%20width=630,%20height=500'))). Invest Ophthalmol Vis Sci. 2008;49:2156-62
134. **Gillies M**. Surrogate marker. Ophthalmology 2008;115:416-7
135. McGimpsey SJ, **Gillies MC**. Treatment of macular degeneration--controversy and hope. Br J Ophthalmol. 2008;92:436-7
136. Zhang X, Bao S, Lai D, Rapkins RW, **Gillies MC**. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 2008;57:1026-33
137. Barthelmes D, **Gillies MC**, Fleischhauer JC, Sutter FK. A case of idiopathic perifoveal telangiectasia preceded by features of cone dystrophy. Eye. 2007;21:1542-3
138. Mohamed Q, **Gillies MC**, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902-16
139. Quin GG, Len AC, Billson FA, **Gillies MC**. Proteome map of normal rat retina and comparison with the proteome of diabetic rat retina: new insight in the pathogenesis of diabetic retinopathy. Proteomics. 2007;7:2636-50
140. **Gillies MC**, Larsson J. The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration. Am J Ophthalmol. 2007;144:134-6
141. **Gillies MC**, Islam FM, Zhu M, Larsson J, Wong TY. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol. 2007;91:1323-6
142. **Gillies MC**, Wong TY. Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 2007 15;356:748-9
143. Chew E, **Gillies MC**, Bird AC. Macular telangiectasia – a simplified classification. Arch Ophthalmol 2006;124:573-4
144. **Gillies MC.** What we don't know about avastin might hurt us (invited editorial).Arch Ophthalmol. 2006;124:1478-9
145. Cherepanoff S, Mitchell P, Wang JJ, **Gillies MC**. Retinal autoantibody profile in early age-related macular degeneration: preliminary findings from the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2006;34:590-5
146. **Gillies MC**, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533-8
147. Sirimaharaj M, Robinson MR, Zhu M, Csaky KG, Donovan B, Sutter F, **Gillies MC**. Intravitreal injection of triamcinolone acetonide for immune recovery uveitis. Retina. 2006;26:578-80
148. **Gillies MC**, Simpson JM, Zhu M. Triamcinolone for occult exudative age-related macular degeneration. Am J Ophthalmol. 2006 ;141
149. Larsson J**, Gillies MC**. Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration. Clin Experiment Ophthalmol. 2005;33:544
150. Larsson J, Zhu M, Sutter F, **Gillies MC**. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol. 2005;139:802-6
151. Wang Y, Li SY, Zhu M, Chen SJ, Liu Y, Men XH, **Gillies M**, Larsson J. Metamorphopsia after successful retinal detachment surgery: an optical coherence tomography study. Acta Ophthalmol Scand. 2005;83:168-71
152. Tretiach M, Madigan MC, Wen L, **Gillies MC**. Effect of Müller cell co-culture on in vitro permeability of bovine retinal vascular endothelium in normoxic and hypoxic conditions. Neurosci Lett. 2005 22;378:160-5
153. **Gillies MC**, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005 ;112:139-43
154. Sutter FK, Simpson JM, **Gillies MC**. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004 ;111:2044-9
155. **Gillies MC**. Is it time yet for intravitreal triamcinolone to be used in routine clinical practice? Clin Experiment Ophthalmol. 2004;32:561-2
156. Tretiach M, Madigan MC, **Gillies MC**. Conditioned medium from mixed retinal pigmented epithelium and Müller cell cultures reduces in vitro permeability of retinal vascular endothelial cells. Br J Ophthalmol. 2004 ;88:957-61
157. **Gillies MC**, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor AB. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004 ;122:336-40
158. van Reyk DM, **Gillies MC**, Davies MJ. The retina: oxidative stress and diabetes. Redox Rep. 2003;8:187-92
159. Sutter KP, **Gillies MC.** Pseudo-Endophthalmitis after Intravitreal Injection of Triamcinolone. A Case Series. Br J Ophthalmol, 2003;87:972-4
160. Sutter KP, **Gillies MC.** Intravitreal Triamcinolone for Radiation-Induced Macular Edema. A Case Report. Arch Ophthalmol, 2003;121:1491-3
161. Tretiach M, van Driel D, **Gillies MC**. Transendothelial electrical resistance of bovine retinal capillary endothelial cells is influenced by cell growth patterns: an ultrastructural study. Clin Experiment Ophthalmol. 2003;31:348-53
162. **Gillies MC**. Evaluation of PMMA intraocular lenses marketed in India: former editor's comment. Clin Experiment Ophthalmol. 2003;31:279
163. **Gillies MC**, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121:667-73
164. Wang JJ, Mitchell P, Smith W, **Gillies M**, Billson F, Blue Mountains Eye Study. Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol. 2003;10:37-48
165. **Gillies MC**. New professionalism and the society journal (Editorial). Clin Exp Ophthalmol. 2002;30:389-91
166. Wang JJ, **Gillies MC**. Closing the gaps between urban and rural eye health and eye care services (Editorial). Clin. Exp Ophthalmol. 2002;30:313-4
167. **Gillies MC**. Clinical and Experimental Ophthalmology online (Editorial). Clin Exp Ophthalmol. 2002;30:315
168. **Gillies MC**. Detection and treatment of diabetic retinopathy (Editorial). Clin Exp Ophthalmol. 2001;29:47
169. Penfold PL, Madigan MC**, Gillies MC** And Provis JM. Immunological and aetiological aspects of macular degeneration. Progr Ret Eye Res2001;20:385-414
170. Penfold PL. Wen L. Madigan MC. **Gillies MC**. King NJ. Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000;121:458-65
171. **Gillies M.** When does neural degeneration occur in diabetic retinopathy? (Editorial). Clin Exp Ophthalmol 2000;28:1-2
172. **Gillies MC**, Brooks AMV, Gillies WE, Young S, Goldberg I**.** A randomised, controlled trial of interferon alpha 2 versus 5 fluorouracil for the prevention of fibrosis after glaucoma filtering surgery. Aust NZ J Ophthalmol 1999;27:37-44
173. **Gillies M.** Attacking cataract blindness (Editorial). Aust NZ J Ophthalmol 1999;27:93-4
174. **Gillies MC**. Regulators of vascular permeability: potential sites for intervention in the treatment of macular oedema. Doc Ophthalmol 97:251-60:1999
175. Challa JK, **Gillies MC**, Penfold PL, Gyory JF, Hunyor ABL, Billson FA. Exudative Macular Degeneration and Intravitreal Triamcinolone: A Pilot Study: 18-month Follow-up. Aust NZ J Ophthalmol 1998;26:277-81
176. **Gillies M**, Donovan B. Ophthalmology and Sexual Health Medicine. Int J STD AIDS 1998;9:311-7
177. **Gillies M**, Brian G, La Nauze J, Le Mesurier R, Moran D, Taylor H, Ruit S. Modern surgery for global cataract blindness - preliminary considerations. Arch Ophthalmol 1998;116:90-2
178. Tobin SN, Dat NQ, Binh P, La Nauze J, **Gillies M**. Extracapsular cataract surgery in Vietnam. A 1 year follow-up study. Aust N Z J Ophthalmol. 1998;26:13-7.
179. **Gillies M**, Sarks J, Dunlop C, Mitchell P, Traumatic retinopathy resembling acute macular neuroretinopathy. Aust NZ JOphthalmol 1997;25:207-10
180. **Gillies M**, Clemett R. The state of the ANZJO (Editorial). Aust NZ J Ophthalmol 1997;25:1-2
181. Langford-Smith J, **Gillies M**, Billson F. Barrier activity of fractionated human serum. Aust NZ J Ophthalmol 1997;25:Suppl 1,S85-6
182. Moran D, **Gillies M**, Brian G, La Nauze J. Low-cost intraocular lenses for cataract patients. Lancet 1997;349:885-6
183. **Gillies MC**, Su T, Stayt J, Simpson JM, Naidoo D, Salonikas C. Effect of high glucose on permeability of retinal capillary endothelium in vitro. Invest Ophthalmol Vis Sci 1997;38:635-42
184. Francis IC, McCluskey PJ, **Gillies M**, Wakefield D, Walls RS. Diagnosis of the conjunctival biopsy in OCP. Ophthalmology 1996;103:543-4
185. **Gillies M**. The society journal (Editorial). Aust NZ J Ophthalmol 1996;24:1-2
186. **Gillies M**, Francis I, McCluskey P, Wakefield D. Local interferon alpha 2b for ocular cicatricial pemphigoid. Br J Ophthalmol 1996;80:927
187. **Gillies M**. Art or science ? (Editorial) Aust NZ J Ophthalmol 1996;24:83-4
188. **Gillies MC**, Garrett SKM, Shina SM, Morlet N, Taylor HR. Topical interferon alpha 2 for corneal haze after excimer laser photorefractive keratectomy. J Cataract Refract Surg 1996;22:891-900
189. **Gillies MC**. Potential uses of interferon in ophthalmological disorders. Clin Immunother 1996;6:383-94
190. **Gillies M**, Goldberg I. Standards (Editorial). Aust NZ J Ophthalmol, 1996;24:166-7
191. Sarks SH, Sarks JP, Arnold JJ, **Gillies MC**, Walter CJ. Prophylactic perifoveal laser treatment of soft drusen. Aust NZ J Ophthalmol 1996;24:15-26
192. **Gillies M** and Su T: Interferon alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res 1995;49:277-288
193. **Gillies M**, Su T and Naidoo D: Electrical resistance and macromolecular permeability of retinal capillary endothelial cells in vitro. Curr Eye Res 1995;14:435-42
194. **Gillies M**, Sarks J, Beaumont P, Hunyor A, McKay D, Kearns M, McClusky P, and Sarks S: Treatment of choroidal neovascularisation in Age Related Macular Degeneration with interferon alpha 2a and 2b. Br J Ophthalmol 1993;77:759-765
195. Morlet N, **Gillies MC**, Crouch R and Maloof T: Effect of topical interferon-alpha 2b on corneal haze after excimer laser photorefractive keratectomy in rabbits. Refract Corneal Surg. 1993;9:443-51.
196. **Gillies M** and Su T: Hyperglycaemia inhibits pericyte contractility in vitro. Invest Ophthalmol Vis Sci. 1993;34:3396-401.
197. **Gillies M**, Goldberg I, Young S, Su T: Glaucoma filtering surgery with interferon alpha 2bJ Glaucoma. 1993 ;2:229-35.
198. **Gillies MC**, Su T, Sarossy MG and Hollows FC. Interferon alpha 2b prevents fetal calf serum induced proliferation of Tenon's capsule fibroblasts in vitro. Graefes Arch Clin Exp Ophthalmol. 1993;231:118-21.
199. Su T and **Gillies MC**. A simple method for the in vitro culture of human retinal capillary endothelial cells. Invest Ophthalmol Vis Sci. 1992;33:2809-13.
200. **Gillies MC** and Su T. Cytokines, fibrosis and the failure of glaucoma filtering surgery. Aust NZ J Ophthalmol, 1991;19:299-303.
201. **Gillies MC** and Mandel TE. The evolution of function and response to challenge and pregnancy of portally and systemically placed islet cell grafts in streptozotocin diabetic mice. Metabolism.1990;39:1253-8
202. **Gillies MC** and Mandel TE. The prevention of diabetic retinal and renal basement membrane thickening in mice by fetal islet cell allografts. Aust NZ J Ophthalmol 1990;18:27-32
203. **Gillies MC** and Mandel TE. Chronic hyperglycaemia in mice does not adversely affect islet cell allograft function. Transplantation 1989;48:523-4
204. **Gillies MC**. The effect of islet cell allografts on diabetic microvascular disease in mice. PhD thesis, Melbourne University, Parkville, Victoria.
205. **Gillies MC** and Mandel TE. The response to glycaemic challenge of portally and systemically grafted fetal islet cell isografts. Trans Proc 1987;19:933
206. Ihle BU and **Gillies MC**. Scurvy and thrombocytopathy in a chronic hemodialysis patient. Aust NZ J Med 1983;13:523

***BOOK CHAPTERS***

1. Sutter FKP, **Gillies MC**, Helbig H. Diabetic Macular Edema: Current Treatments. In Holz, FG, Spaide RF eds., Medical Retina. Springer-Verlag Berlin 2007
2. Mohamed Q, **Gillies MC**, Wong TY. Management of Diabetic Retinopathy: A Systematic Review. In: Scott IU, Flynn HW, Smiddy WE eds. Diabetes and Ocular Disease (Monograph 14), Second Edition, The Foundation of the American Academy of Ophthalmology. San Francisco 2008.
3. **Gillies MC**. The role of intravitreal steroids in the management of diabetic retinopathy. In Duh E ed, Diabetic retinopathy, Humana. 2009

***NON PEER REVIEWED AND LAY-PRESS***

1. Intravitreal Triamcinolone for AMD appears promising, but more studies needed. Ophthalmology Times July 1 2002
2. Treatments of Retinopathy. Diabetes Management Journal 2002;8:8
3. Until guidelines emerge, surgeons urge caution in emplying triamcinolone for AMD. Ocular Surgery News May 2003
4. Intravitreal Triamcinolone for DME shows lasting efficacy. Diabetic Microvascular Complications Today 2005;2:28-29
5. Steroids trial beats diabetes blindness. The Weekend Australian September 9-10, 2006, p22 (Health)
6. New Developments in the management of Diabetic Retinopathy. Diabetes Management Journal 2007;19:10
7. Steroids treatment can prevent diabetic blindness: Sydney Eye Hospital Study. INSIGHT, September 2006
8. The role of intravitreal steroids in the management of diabetic retinopathy. The Observatory 2007;1: 9-11.

**GRANTS**

**COMPETITIVE**

1. Researchers: Gillies MC, Shen W, Chung SH

Title: Differentiation of Muller glial cells from human stem cells for therapeutic use by promoting the Notch signalling pathway.

Source: CDIP Fund, the University of Sydney 2017 ($35,000)

1. Researchers: Gillies MC, Shen W, Chung SH

Title: Differentiation of Muller glial cells from human stem cells for therapeutic use by promoting the Notch signalling pathway.

Source: CDIP Grant, The University of Sydney, 2016 ($35,000)

1. Researchers: Gillies MC

Title: Clinical Trials and Registries to prevent blindness for Macular Disease

Source: NHMRC Practitioner Fellowship Grant: 2016-20

1. Researchers: Gillies MC

Title: How to get the best outcomes of treatment of neovascular age-related macular degeneration with vascular endothelial growth factor inhibitors: Real World Evidence

Source: Macular Disease Foundation Australia Research Grant: 2016-18

1. Researchers: Chung SH, Gillies MC

Title: Use patient-derived stem cells to model macular telangiectasia type 2 in a dish.

Source: ORIA New Investigator Grant: 2016 ($49500)

1. Researchers: Gillies MC

Title: An Observational Study of the Outcomes of Treatment of Neovascular Age-Related Macular Degeneration with ranibizumab and aflibercept.

Source: Bridging Support Grant, The University of Sydney 2015 ($30000)

1. Researchers**:** Gillies MC

Title: Comparison of Müller cells isolated from the human macula and peripheral retina.

Source: Ophthalmic Research Institute of Australia 2015 ($50 000)

1. Researchers**:** Gillies MC

Title:University of Sydney Equipment Grant, *NGC QUEST 10 plus Chromatography System*

Source: Equipment Grant, The University of Sydney 2015 ($74,679)

1. Researchers**:** Gillies MC, Zhu L

Title: The novel treatment of retinal diseases targeting at Retinol Binding Protein 3 dysregulation.

Source: Ophthalmic Research Institute of Australia 2014 ($50 000)

1. Researchers: Gillies MC  
   Title: The contribution of Muller cell dysfunction to retinal neuronal and vascular pathology

Source: Bridging Support Grant,The University of Sydney Jan 2014-Dec 2014 ($30,000)

1. Researchers: Gillies MC, Shen W, McAvoy J, Zhu L

Title: The contribution of aberrant Wnt signalling to neuronal and vascular pathology in retinal disease

Source: NHMRC Project Grant # APP1050373: 2013-2015 ($541,967)

1. Researchers: Gillies MC, Shen W, Barnett N.

Title: Glial-Neuronal-Vascular Interactions In A Novel Transgenic Model Of Muller Cell Dysfunction

Source: NHMRC Project Grant #APP1028393: 2012-2014 ($605,355)

1. Researchers: Gillies MC

Title: Practitioner Fellowship - PF Level 1

Source: NHMRC Practitioner Fellowship: 2011-2015 ($428,869)

1. Researchers: Gillies MC  
   Title: Role of Muller glial dysfunction in retinal diseases

Source: DVC Research/Bridging Support Grant, The University of Sydney APP#1008872: Jan 2011-Dec 2011 ($50,000)

1. Researchers: Gillies MC, McAllister I, Morlet N and Keeffe J.  
   Title: Ongoing prospective audit using high quality data and database linkage to improve the outcomes of macular disease.

Source: NHMRC Project Grant #632663: 2010-2012 ($813,550)

1. Researchers: Gillies MC, Kaines A and Fraser-Bell S.   
   Title: Clinical trial of intravitreal injections of dexamethasone vs bevacizumab in diabetic foveal oedema resistant to laser.

Source: NHMRC Project Grant #632667: 2010-2012 ($324,375)

1. Researchers: Gillies MC and Shen WY.

Title: Regulation of bone marrow derived progenitor cells for diabetic retinopathy.

Source: NHMRC Project Grant #632839: 2010-2012 ($427,175)

1. Researchers: Burdon K, Craig J, Gillies MC, Petrovsky N,Daniell M and Charlesworth J.

Title: A genome-wide association scan to identify genetic risk factors for sight threatening diabetic retinopathy.

Source: NHMRC Project Grant #595918.2010-2012 ($952,688)

1. Researchers: Shen W and Gillies MC

Title: The use of a digital retinal camera to monitor vascular repair by bone marrow progenitor cells in diabetic retinopathy

Source: Rebecca L. Cooper Medical Research Foundation 2007 ($20 000).

1. Researchers: Gillies MC, Zhu M

Title : Extension of a clinical trial of intravitreal triamcinolone for diabetic macular oedema (TDMX study)

Source: NHMRC Project Grant #402573 :2006 - 2008 ($164,288)

1. Researchers: Gillies MC, Wong TY, McAllister I

Title: A multicentre randomised clinical trial of laser treatment plus intravitreal triamcilone for diabetic macular oedema

Source : NHMRC Project grant #352312 : 2005 – 2008 ( $512,500)

1. Researchers**:** Gillies MC, Windsor M, Hunyor A, Len A

Title: The role of wnt signaling in the pathogenesis of diabetic retinopathy

Source: Ophthalmic Research Institute of Australia 2007 ($40 000)

1. Researchers:Gillies MC, Windsor M, Hunyor A, Len A

Title: Proteomic analysis of a library of vitreous samples to study abnormal protein profiles in eyes with diabetic retinopathy

Source:Ophthalmic Research Institute of Australia 2006 ($40 467)

1. Researchers:Gillies MC, Larsson J, Windsor M

Title: In vivo studies of intravitreal triamcinolone acetonide (IVTA) treatment of retinopathy in the diabetic rat

Source: Ophthalmic Research Institute of Australia/Royal Australian and New Zealand College of Ophthalmologists Eye Foundation 2005 ($32 500)

1. Researcher: Gillies MC

Equipment: HRA2 fundus camera

Source: Sydney Eye Hospital Foundation 2006 ($160 000)

1. Researcher: Gillies MC

Title: A randomized clinical trial of intravitreal Triamcinolone for diabetic macular oedema

Source: Ophthalmic Research Institute of Australia 2004 ($30 000)

1. Researchers: Gillies MC, Sutter F

Title: A randomized clinical trial of intravitreal Triamcinolone for diabetic macular oedema

Source: Juvenile Diabetes Research Foundation (#1-2003-767) 2003-2005 (US$110 000)

1. Researchers: Gillies MC and Sutter F

Title: Triamcinolone for diabetic macular oedema study

Source: Sydney Eye Hospital Foundation 2003 ($30 000)

1. Researchers: van Reyk D and Gillies MC

Title: Oxidative stress, tyrosine phosphorylation and vascular permeability in diabetic retinopathy.

Source: Diabetes Australia Research Trust 2002 ($38 526)

1. Researcher: Gillies MC

Title: The effect laser treatment on retinal vascular permeability

Source: Ophthalmic Research Institute of Australia 2002 ($41 000)

1. Researcher: Gillies MC

Equipment: Optical Coherence Tomographer

Source: Sydney Eye Hospital Foundation 2002 ($95 000)

1. Researchers: Gillies MC, Wyndham J, Collier S

Title: The effect matrix metalloproteinases on the permeability of retinal vascular endotheial cells in vitro

Source: Ophthalmic Research Institute of Australia 2001 ($34 000)

1. Researchers: Eutick M, Penfold P, Gillies MC, Bilson F

Title: Development of intravitreal triamcinolone for ARMD

Source: COMET (ref #243) Australian Federal Government Commerce Development Scheme 2000 ($100 000)

1. Researchers: Gillies M, Luo W

Title: Data analysis of the intravitreal triamcinolone study

Source: Sydney Eye Hospital Foundation 2000 ($48 000)

1. Researchers: Gillies MC

Title: The effect of retinal laser treatment on the permeability of retinal capillary endothelial cells in vitro.

Source: University of Sydney Research Grants Scheme 2000 ($20 000)

1. Researcher: Gillies MC

Title: The effect of retinal laser treatment on the permeability of retinal capillary endothelial cells in vitro.

Source: Diabetes Australia Research Trust 2000 ($34 000)

1. Researchers: McAllister I, Mitchell P, Gillies MC

Title: Chorioretinal anastamosis for central retinal vein occlusion

Source: NHMRC 2000-2002 ($24 000)

1. Researcher: Gillies MC

Title: Blood-retinal barrier permeability and tyrosine phosphorylation of junctional complexes

Source: NHMRC 1997-1999 ($143 597)

1. Researchers: Gillies MC, Hunyor A, Billson F, Penfold P, Simpson J

Title: Intravitreal triamcinolone for exudative age-related macular degeneration

Source: PHRDC 1997-1999 ($140 325)

1. Researcher: Gillies MC

Title: The role of protein kinase C activation in diabetic retinopathy

Source: Ophthalmic Research Institute of Australia 1997 ($46 000)

1. Researcher: Gillies MC

Title: The role of protein kinase C activation in diabetic retinopathy

Source: Diabetes Australia Research Foundation 1997 ($15 000)

1. Researcher: Gillies MC

Title: Effect of tyrosine phosphorylation of tight junction associated proteins on the permeability of retinal capillary endothelial cells in vitro

Source: Ophthalmic Research Institute of Australia 1996 ($31000)

1. Researcher: Gillies MC

Title: Effect of high glucose on an in vitro model of the blood-retinal barrier

Source: Ophthalmic Research Institute of Australia 1995 ($14 500)

1. Researcher: Gillies MC

Title: Effect of high glucose on an in vitro model of the blood-retinal barrier

Source: Kellion and Diabetes Australia Research Foundation 1995 ($30 500)

1. Researchers: Taylor HR and Gillies MC

Title: The effect of topical interferon alpha 2b on fibrosis after excimer laser photorefractive keratectomy in humans

Source: Schering Plough Corporation 1994 ($30 000)

1. Researchers: Gillies MC, Goldberg I, Brookes A

Title: The effect of subconjunctival interferon alpha 2b on fibrosis after glaucoma surgery in humans

Source: Schering Plough Corporation 1994 ($100 000)

1. Researchers: Gillies MC, Morlet N, Maloof A.

Title: The effect of topical interferon alpha 2b on fibrosis after excimer laser photorefractive keratectomy in rabbits

Source: Schering Plough Corporation 1993 ($20 000)

1. Researcher: Gillies MC

Title: An in vitro model of the blood-retinal barrier

Source: Centenary Foundation, Eastern Area Health Service 1992 ($14 000)

1. Researcher: Gillies MC

Title: Effect of high glucose on an in vitro model of the blood-retinal barrier.

Source: Mather Trust Fund UNSW 1992 ($8 000)

1. Researcher: Gillies MC

Title: The effect of interferon alpha 2 on ocular fibroblast proliferation in vitro

Source: Schering Plough Corporation 1992 ($15 000)

1. Researcher: Gillies MC

Title: An in vitro model of the blood-retinal barrier

Source: Juvenile Diabetes Foundation Australia 1991 ($24 000)

1. Researchers: Su T and Gillies MC

Title: In vitro culture of bovine and human retinal capillary endothelium and pericytes

Source: Ely Lily Post Graduate Medical Research Fellowship 1990 ($30,000)

**EQUIPMENT GRANTS - Awarded to SSI since 2000, applicant was a CI on each**

***University of Sydney Major Equipment scheme***

2001 - Molecular Biology Workstation, $55,000

2002 - Confocal Microscope, $98,600

2003 - Tissue Processor and Embedding Centre, $36,500

2006 - MALDI TOF Mass Spectrometer, $147,000

2007- New Laboratory Construction (top floor central block), $200,000

***NHMRC equipment grants***

2002 - Rotary and Manual Microtomes, $16,040

2004 - Inverted Fluorescence Microscope Workstation, $31,694

2005 - High Pressure Liquid Chromatography (HPLC) system, $72,790

2007 - Tecan Infinite M200 monochromator microplate reader and detector plus software, $47,628

***Sydney Eye Hospital Foundation***

2002 - Confocal Microscope, $33,780

2004 - Inverted Fluorescence Microscope Workstation, $24,588

2006 - MALDI TOF Mass Spectrometer, $85,000

***Ramaciotti Foundations***

2002 - Confocal Microscope, $15,000

2004 - Tissue Processor and Embedding Centre, $30,000

***Honda Foundation***

2004 - Inverted Fluorescence Microscope Workstation, $13,302

***Lions NSW-ACT Save Sight Foundation***

2001 - Molecular Biology Workstation, $46,861

2006 - Syngene gel documentation system, $80,000

***Rebecca Cooper Foundation***

2004 - Factors involved in vascularisation, $12,894

2005 - MALDI TOF Mass Spectrometer, $15,000

2006 - Proteomics based investigations, $20,000

***Trust Foundation Ltd***

2007 - Sorvall WX90 floor standing ultracentrifuge, $20,000

**RESEARCH STAFF**

LABATORY RESEARCH UNIT

|  |  |
| --- | --- |
| Research fellow | Dr Weiyong Shen |
| Post Docs | Dr Ling Zhu  Dr Sook Chung |
| Research Assistant | Ms So Ra Lee |
| Research Officer | Dr Svetlana Cherepanoff  Ms Lay Khoon Too |

CLINICAL RESEARCH UNIT

|  |  |
| --- | --- |
| Project Manager (Save Sight Registries) | Jr Dymow Barbosa |
| Research Administration Officer (Save Sight Registries) | Ms Sweety Mathews  Ms Hannah Ahern |
| Project Support Officer (Save Sight Registries ) | Mr Robert Medynski |
| Biostatstician (Save Sight Registries) | Mr Vuong Nguyen (0.8FTE) |
| Project IT (Save Sight Registries) | Mr Marco Garcia |
| Clinical Research Manager | Mrs Maria Williams |
| Clinical Research Officers | Mrs Amanda Dinh  Mrs Haipha Ali  Ms Sharon McKenzie  Miss Winnie Zhang  Mrs Kathleen Agorto  Miss Stella Xu  Miss Liza Shilpakar |
| Clinical Fellows | Dr Shaan Liem  Dr Elissa Cornish |